Rankings
▼
Calendar
ALGS FY 2025 Earnings — Aligos Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ALGS
Aligos Therapeutics, Inc.
$45M
FY 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-44.6% YoY
Gross Profit
$1M
57.5% margin
Operating Income
-$88M
-4024.9% margin
Net Income
-$24M
-1106.7% margin
EPS (Diluted)
$-2.45
Cash Flow
Operating Cash Flow
-$83M
Free Cash Flow
-$83M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$89M
Total Liabilities
$35M
Stockholders' Equity
$54M
Cash & Equivalents
$18M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$4M
-44.6%
Gross Profit
$1M
$4M
-68.2%
Operating Income
-$88M
-$89M
+1.3%
Net Income
-$24M
-$131M
+81.6%
← Q4 2024
All Quarters
Q1 2025 →